Structured evidence table for Alpha Gpc Memory Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Alpha Gpc Memory Meta-Analysis | As measured by the Sandoz Clinical Assessment for Geriatric Patients (SCAG), choline alphoscerate significantly improved clinical conditions in patients with dementia disorders compared with citicoline at the end of treatment [WMD: -3.92 (95% CI: -7.41 to -0.42)]. | 1 | Sagaro GG (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. |
| Alpha Gpc Memory Meta-Analysis | Conclusion Our findings indicate that choline alphoscerate is more effective than citicoline in improving the clinical conditions of dementia patients. | 1 | Sagaro GG (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. |
| Alpha Gpc Memory Meta-Analysis | Background Over 44 million people worldwide live with dementia, affecting their quality of life and well-being. | 1 | Sagaro GG (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. |
| Alpha Gpc Memory Meta-Analysis | Choline alphoscerate and citicoline supplements are commonly used to improve cognitive function in dementia patients. | 1 | Sagaro GG (2025) | Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. |
| Alpha Gpc Memory Meta-Analysis | Although L-α-GPC has been discussed in both neurodegenerative and vascular-related cognitive disorders, the available evidence remains heterogeneous. | 4 | Putri Vannisa Artasya (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders |
| Alpha Gpc Memory Meta-Analysis | Therefore, a careful and contextualized interpretation of the literature is necessary, particularly when comparing evidence across Alzheimer’s disease, Parkinson’s disease-related cognitive decline, and cognitive impairment associated with cerebrovascular conditions. | 4 | Putri Vannisa Artasya (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders |
| Alpha Gpc Memory Meta-Analysis | Given this background, the present narrative review focuses primarily on the mechanistic and clinical evidence regarding L-α-GPC in cognitive decline associated with neurodegenerative disorders, while also acknowledging relevant findings from studies of vascular- or cerebrovascular-related cognitive impairment where appropriate. | 4 | Putri Vannisa Artasya (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders |
| Alpha Gpc Memory Meta-Analysis | 1 2 Neurodegeneration involves the progressive loss of neuronal structure and function, leading to cognitive and motor impairments. | 4 | Putri Vannisa Artasya (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders |
Source documents